AI could revolutionize antibiotics — but the market is standing in the way

This article argues that although artificial intelligence could significantly accelerate antibiotic discovery—by screening millions of molecules, identifying hidden antimicrobial compounds in genomic data, and designing entirely new drug structures—the main barrier to solving antimicrobial resistance is economic, not technological. The antibiotic market provides weak financial incentives because new antibiotics are used sparingly and for short treatment courses, which limits revenue and discourages investors from funding expensive late-stage development. As a result, the antibiotic pipeline remains thin, with only a small number of drugs targeting the most dangerous pathogens and few truly novel classes in development. The authors conclude that AI-driven innovation alone cannot solve the AMR crisis without major policy and market reforms—such as new funding mechanisms or “delinked” incentives—to make antibiotic development financially viable.